Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late ...

Cassava Sciences is laying off 10 employees —a third of its workforce—as the biotech seeks to conserve cash in the wake of ...

Cassava Science provided a business update. In November 2024, Cassava reported that the topline results from the Phase 3 RETHINK-ALZ study ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 13.11% ...

Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer's disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment inclu ...

We hoped industry layoffs would relent in 2024. That's not what happened. | As always, if you know of layoffs occurring at a ...

NEW YORK, NY / ACCESSWIRE / January 5, 2025 / If you suffered a loss on your Cassava Sciences, Inc. (NASDAQ:SAVA) investment and want to learn ...

OneAmerica Financial® announced today that by March 2025, all full-time associates will have the opportunity to earn $22 per hour or more through a combination of their base pay and bonus plan ?

The Association for Talent Development (ATD) is partnering with The University of Pennsylvania Graduate School of Education (Penn GSE) to offer a certificate program for talent development leaders.

H.C. Wainwright has recently reduced Cassava Sciences Inc (SAVA) stock to Neutral rating, as announced on November 26, 2024, according to Finviz. Earlier, on October 8, 2024, H.C. Wainwright had ...

Specifically, Defendants misrepresented and/or failed to disclose that: (1) Cassava’s drug, simufilam, was not capable of abating the progression of Alzheimer’s Disease, even in mild to ...

Notable profits for the buyer who lifted the $0.25 offer for 9,851 Cassava Sciences (SAVA) Feb-25 3 calls yesterday at 10:51ET when underlying shares were trading at $2.65. Shares closed at $2.75 ...